Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q3 2017 · 10-Q
Revenue$111.98K$111.98K+10.7% vs Q3 2016 Net Income$48.88K$48.88KN/M vs Q3 2016 EPS Diluted$0.00$0.00N/M vs Q3 2016 Gross Profit$80,090+27.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flowderived$23,796N/M Margins · derivedGross margin71.5%+9.3 pt vs Q3 2016
Operating margin45.4%+255.0 pt vs Q3 2016
Net margin43.7%+255.2 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end